SCHEMBL14286284

SCHEMBL14286284

Cc1ccc(NC(=O)c2ccc(C)c(C(F)(F)F)c2)cc1Nc1nc(-c2cccnc2)cs1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 15/20 0.68
BCR P11274 11/20 0.68
KDR P35968 5/20 0.68
PDGFRB P09619 3/20 0.68
HDAC3 O15379 2/20 0.68
HDAC4 P56524 2/20 0.68
HDAC1 Q13547 2/20 0.68
HDAC7 Q8WUI4 2/20 0.68
HDAC2 Q92769 2/20 0.68
HDAC10 Q969S8 2/20 0.68
HDAC11 Q96DB2 2/20 0.68
HDAC8 Q9BY41 2/20 0.68
HDAC6 Q9UBN7 2/20 0.68
HDAC9 Q9UKV0 2/20 0.68
HDAC5 Q9UQL6 2/20 0.68
KIT P10721 4/20 0.65
PDGFRA P16234 4/20 0.65
EGFR P00533 1/20 0.65
ERBB2 P04626 1/20 0.65
LCK P06239 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025205 0.97 ABL1 (0.70) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL715868 0.89 ABL1 (0.69) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL14286283 0.89 ABL1 (0.71) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL14286289 0.89 ABL1 (0.71) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL716834 0.88 ABL1 (0.69) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL5023634 0.88 ABL1 (0.64) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL5972230 0.88 ABL1 (0.60) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL15629424 0.88 ABL1 (0.68) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL716396 0.88 ABL1 (0.75) ABL1BCRKDRPDGFRBHDAC3
SCHEMBL5023760 0.88 ABL1 (0.58) ABL1BCRKDRPDGFRBHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis AB SCIENCE 2008-01-31 US disclosed
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis AB SCIENCE 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis KIT, CMA1, CPA3 ABL1 8/4885BCR 41/4885KDR 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.